Hyperfine (HYPR) Cash from Financing Activities (2021 - 2026)
Hyperfine's (HYPR) quarterly Cash from Financing Activities came in at $14.5 million in Q1 2026, up 159.51% YoY from $5.6 million in Q1 2025, and down 24.87% on a QoQ basis from $19.3 million in Q4 2025.
Hyperfine (HYPR) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Hyperfine (HYPR) has 6 years of Cash from Financing Activities data on file, last reported at $14.5 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 159.51% year-over-year to $14.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.4 million (up 456.16% YoY) and the FY2025 annual result came in at $27.5 million, up 2598.92% from the prior year.
- Cash from Financing Activities retreated to $14.5 million in Q1 2026, from $19.3 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $19.3 million in Q4 2025 to a low of $5000.0 in Q4 2022.
- A 5-year average of $3.1 million and a median of $58500.0 in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities slumped 100.0% — and 2025, when it jumped 35607.41%.
- Tracing HYPR's Cash from Financing Activities over 5 years: stood at $5000.0 in 2022, then surged by 460.0% to $28000.0 in 2023, then surged by 92.86% to $54000.0 in 2024, then jumped by 35607.41% to $19.3 million in 2025, then dropped by 24.87% to $14.5 million in 2026.
- The last three Cash from Financing Activities figures came in at $14.5 million (Q1 2026), $19.3 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.44 Bn | 193.84 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 127.32 Bn | 123.85 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 51.90 Bn | 47.65 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 34.30 Bn | 32.36 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 33.74 Bn | 31.63 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.05 Bn | 22.56 Bn | 684.20 Mn | -213.50 Mn |
| 10 | Hyperfine | 88.36 Mn | 43.60 Mn | 1.98 Mn | 10.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.78 Mn |
| Jun 30, 2026 | 10.78 Mn |
| Mar 31, 2026 | 14.49 Mn |
| Mar 31, 2026 | 14.49 Mn |
| Dec 31, 2025 | 19.28 Mn |
| Dec 31, 2025 | 19.28 Mn |
| Sep 30, 2025 | 2.16 Mn |
| Sep 30, 2025 | 2.16 Mn |
| Jun 30, 2025 | 474,000.00 |
| Jun 30, 2025 | 474,000.00 |
| Mar 31, 2025 | 5.58 Mn |
| Mar 31, 2025 | 5.58 Mn |
| Dec 31, 2024 | 54,000.00 |
| Dec 31, 2024 | 54,000.00 |
| Sep 30, 2024 | 851,000.00 |
| Sep 30, 2024 | 851,000.00 |
| Jun 30, 2024 | 59,000.00 |
| Jun 30, 2024 | 59,000.00 |
| Mar 31, 2024 | 55,000.00 |
| Mar 31, 2024 | 55,000.00 |